IMU 5.88% 5.4¢ imugene limited

Ann: Imugene completes Phase 1a trial of immunotherapy PD1-Vaxx, page-56

  1. 24 Posts.
    lightbulb Created with Sketch. 17
    Whilst I am excited about this announcement, there is no explicit mention of a partnership (e.g. supply agreement) with Roche. It just states that they will be combining with Roche's Tecentriq. Similar to their announcement that they will be combining Her-Vaxx with Keytruda, there is no explicit mention of a partnership with Merck USA. We are only aware of the partnerships with Merck Germany, Pfizer, Cellularity and Eureka. I think jarpan's question was fair.
 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
(20min delay)
Last
5.4¢
Change
0.003(5.88%)
Mkt cap ! $396.8M
Open High Low Value Volume
5.1¢ 5.7¢ 5.1¢ $1.713M 31.55M

Buyers (Bids)

No. Vol. Price($)
9 623619 5.4¢
 

Sellers (Offers)

Price($) Vol. No.
5.5¢ 50000 1
View Market Depth
Last trade - 16.10pm 10/07/2024 (20 minute delay) ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.